Singapore: Takeda Pharmaceutical and H. Lundbeck A/S have submitted a new drug application (NDA) to the US Food and Drug...
Singapore: Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a po...
Singapore: The US FDA has approved GSK and Pfizer-owned HIV dedicated firm, ViiV Healthcare's, Tivicay (dolutegravir) 50...
Singapore: FibroGen and Japanese company Astellas Pharma have initiated the first clinical study in the phase III clinic...
Singapore: Antisense Therapeutics, an Australian publicly listed biopharmaceutical drug discovery and development compan...
Singapore: US FDA has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin table...
Singapore: Eli Lilly and Company has outlined its strategies to face patent cliff expected in 2014. In a statement to in...
Singapore: Asia share of global GDP, measured in purchasing power, has increased from 26.8 percent in 2001 to 33.8 perce...
Singapore: Novo Nordisk's 56-week double-blind phase IIIa clinical trial with liraglutide has shown that it has the pote...
Singapore: A novel anti-TB drug has generated encouraging results in a recent Phase II trial funded by the non-profit TB...
Singapore: For glaucoma patients, taking daily medication will soon become a thing of the past. With Nanyang Technologic...
Singapore: BioDuro, a PPD Company, has opened a new state-of-the-art laboratory in Shanghai, China, strengthening its ab...
Singapore: Sanofi and Regeneron Pharmaceuticals have received US Food and Drug Administration (FDA) approval for ZALTRAP...
Singapore: Exclusivity is everything in the pharmaceutical brand business. Without it, power over pricing disappears and...
Singapore: Eisai has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multi...
Singapore: Australia-based QRxPharma is proceeding with US FDA to discuss the company's Moxduo new drug application (NDA...
Singapore: Japan-headquartered Daiichi Sankyo has completed patient enrollment in the global Hokusai-VTE phase III study...
Singapore: Daiichi Sankyo and Amplimmune have entered into a strategic collaboration to develop a new therapeutic prote...
